ଟୋଫାସିଟିନିବ

ଟୋଫାସିଟିନିବ
Clinical data
Trade names	Xeljanz, Jaquinus, Tofacinix, Others
Synonyms	CP-690550
AHFS/Drugs.com	monograph
MedlinePlus	a613025
data	EU EMA: yes; US DailyMed: Tofacitinib;
Pregnancy; category	AU: D ; US: N (Not classified yet) ; ;
Routes of; administration	By mouth (tablets)
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) ; US: ℞-only ; EU: Rx-only ; ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	74%
Protein binding	40%
Metabolism	Liver (via CYP3A4 and CYP2C19)
Elimination half-life	3 hours
Excretion	Urine
Identifiers
	IUPAC name 3-[(3R,4R)-4-Methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile;
ECHA InfoCard	100.215.928
Chemical and physical data
Formula	C16H20N6O
Molar mass	୩୧୨.୩୮ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N;
	InChI InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1; Key:UJLAWZDWDVHWOW-YPMHNXCESA-N;

ଟୋଫାସିଟିନିବ, ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ଏକ ବିକ୍ରୟ ନାମ ଜେଲଜାନଜ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ରିଉମାଟଏଡ ଆର୍ଥ୍ରାଇଟିସ, ସୋରିଆଟିକ୍ ଗଣ୍ଠି ପ୍ରଦାହ, କିଶୋର ଅକାରଣ ଗଣ୍ଠି ପ୍ରଦାହ ଏବଂ ଅଲସରେଟିଭ କୋଲାଇଟିସ ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୬] ଯେତେବେଳେ ଅନ୍ୟ କୌଣସି ଚିକିତ୍ସା ଫଳପ୍ରଦ ହୁଏ ନାହିଁ, ସେତେବେଳେ ଏହା ବ୍ୟବହୃତ ହୁଏ ।^[୨] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୬]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ତରଳ ଝାଡ଼ା, ମୁଣ୍ଡବିନ୍ଧା ଏବଂ ଉଚ୍ଚ ରକ୍ତଚାପ ହୋଇପାରେ ।^[୬] ଗମ୍ଭୀର ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ସଂକ୍ରମଣ, କର୍କଟ ରୋଗ, ଆଞ୍ଜିଓଇଡିମା ଏବଂ ଫୁସଫୁସ ଏମ୍ବୋଲିଜ୍ମ ହୋଇପାରେ ।^[୬] ଅଧିକ ମାତ୍ରାରେ ଏହି ଔଷଧ ଦେଲେ ମୃତ୍ୟୁ ଆଶଙ୍କା ରହିପାରେ ।^[୬] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର ଶିଶୁର କ୍ଷତି କରିପାରେ ।^[୭] ଏହା ଏକ ପ୍ରକାର ଜାନସ କାଇନେଜ (JAK) ପ୍ରତିବନ୍ଧକ ଔଷଧ ।^[୬]

୨୦୧୨ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏବଂ ୨୦୧୭ରେ ୟୁରୋପରେ ଡାକ୍ତରୀ ବ୍ୟବ‌ହାର ପାଇଁ ଟୋଫାସିଟିନିବ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୬]^[୨] ଯୁକ୍ତରାଜ୍ୟରେ ଏହି ଔଷଧ ଦୈନିକ ଦୁଇଥର ୫ ମିଗ୍ରା ହିସାବରେ ୪ ସପ୍ତାହର ଚିକିତ୍ସା ପାଇଁ ୬୯୦ ପାଉଣ୍ଡ ଖର୍ଚ୍ଚ ହୁଏ ।^[୮] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ପରିମାଣ ଔଷଧର ମୂଲ୍ୟ ପ୍ରାୟ ୪,୬୦୦ ଡଲାର ଅଟେ ।^[୯]

ଆଧାର[ସମ୍ପାଦନା]

↑ ^୧.୦ ^୧.୧ "Tofacitinib Use During Pregnancy". Drugs.com. 15 April 2020. Archived from the original on 29 November 2020. Retrieved 23 October 2020.
↑ ^୨.୦ ^୨.୧ ^୨.୨ "Xeljanz EPAR". European Medicines Agency (EMA). Archived from the original on 28 October 2020. Retrieved 3 November 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
↑ "10 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 13 October 2020. Archived from the original on 27 July 2019. Retrieved 3 November 2020.
↑ "Xeljanz 11 mg prolonged release tablets - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 9 August 2020. Retrieved 3 November 2020.
↑ "Xeljanz- tofacitinib tablet, film coated Xeljanz XR- tofacitinib tablet, film coated, extended release Xeljanz- tofacitinib solution". DailyMed. 2 October 2020. Archived from the original on 30 November 2020. Retrieved 3 November 2020.
↑ ^୬.୦ ^୬.୧ ^୬.୨ ^୬.୩ ^୬.୪ ^୬.୫ ^୬.୬ "Tofacitinib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 28 September 2021. Retrieved 5 October 2021.
↑ "Tofacitinib Use During Pregnancy | Drugs.com". Drugs.com. Archived from the original on 29 November 2020. Retrieved 5 October 2021.
↑ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1168. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
↑ "Tofacitinib Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 5 October 2021.

[Drugs.com_Pregnancy-1] ୧.୦ ^୧.୧ "Tofacitinib Use During Pregnancy". Drugs.com. 15 April 2020. Archived from the original on 29 November 2020. Retrieved 23 October 2020.

[Xeljanz_EPAR-2] ୨.୦ ^୨.୧ ^୨.୨ "Xeljanz EPAR". European Medicines Agency (EMA). Archived from the original on 28 October 2020. Retrieved 3 November 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[3] "10 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 13 October 2020. Archived from the original on 27 July 2019. Retrieved 3 November 2020.

[4] "Xeljanz 11 mg prolonged release tablets - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 9 August 2020. Retrieved 3 November 2020.

[Xeljanz_FDA_label-5] "Xeljanz- tofacitinib tablet, film coated Xeljanz XR- tofacitinib tablet, film coated, extended release Xeljanz- tofacitinib solution". DailyMed. 2 October 2020. Archived from the original on 30 November 2020. Retrieved 3 November 2020.

[AHFS2021-6] ୬.୦ ^୬.୧ ^୬.୨ ^୬.୩ ^୬.୪ ^୬.୫ ^୬.୬ "Tofacitinib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 28 September 2021. Retrieved 5 October 2021.

[7] "Tofacitinib Use During Pregnancy | Drugs.com". Drugs.com. Archived from the original on 29 November 2020. Retrieved 5 October 2021.

[BNF80-8] BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1168. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[9] "Tofacitinib Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 5 October 2021.

[୧]

[୩]

[୪]

[୫]

[୨]

[୬]

[୭]

[୮]

[୯]